Amgen researchers confirm the lackluster data on the KRAS G12C drug AMG 510 reported at ESMO — but they still have a long way to go exploring options

We learned at ESMO that Amgen’s star cancer drug, the pioneering KRAS G12C player AMG 510, tended toward the unimpressive when applied outside non-small cell lung cancer. And the research team has another batch of data to back that up for ASCO. In their CodeBreak100 study, investigators reported on 25…

Click to view original post